Treatment of Gram-positive left-sided infective endocarditis with daptomycin

Area of Science:

• Infectious Diseases
• Cardiology
• Pharmacology

Background:

• Left-sided infective endocarditis (IE) poses significant clinical challenges.
• Effective antibiotic therapy is crucial for managing IE, particularly with resistant pathogens.
• Daptomycin is a lipopeptide antibiotic with activity against Gram-positive bacteria, including Staphylococcus aureus.

Purpose of the Study:

• To evaluate the clinical effectiveness and safety of daptomycin monotherapy in patients with left-sided infective endocarditis.
• To assess microbiological, biochemical, and radiological outcomes in patients treated with daptomycin.
• To identify potential side effects associated with daptomycin use in this patient population.

Main Methods:

• Retrospective analysis of 14 patients diagnosed with left-sided IE based on modified Duke criteria.
• Patients received daptomycin as monotherapy or as a modified treatment regimen.
• Outcomes assessed included clinical improvement, microbiological eradication, and adverse events.

Main Results:

• Daptomycin treatment led to improvements in microbiological, biochemical, and radiological findings, alongside physical examination.
• The primary pathogens identified were methicillin-resistant Staphylococcus aureus (MRSA), Streptococcus mutans, and methicillin-sensitive Staphylococcus aureus (MSSA).
• Thirteen of fourteen patients were discharged in good condition; one patient died due to advanced cardiac failure. Minimal CPK level elevations were the most common side effect, resolving post-treatment.

Conclusions:

• Daptomycin demonstrated successful clinical outcomes and a favorable safety profile in patients with left-sided infective endocarditis.
• The antibiotic can be considered a viable treatment option for left-sided IE, even with challenging pathogens like MRSA.
• Larger patient series are warranted to further support the use of daptomycin in managing left-sided infective endocarditis.